Mode
Text Size
Log in / Sign up
N/A N=49 Randomized Single-blind Treatment

Motor Imagery Intervention for Improving Gait and Cognition in the Elderly

Motor Activity

Enrolled (actual)
49
Serious AEs
2.0%
Results posted
Jun 2024
Primary outcome: Primary: Change in Walking Speed During Single and Dual-task Walking Conditions — -3.33; -0.53; 5.89; -10.55 centimeters per second

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Imagined Gait Intervention (Behavioral); Visual Imagery Intervention (Behavioral)
Age
Older Adult · 65+ yrs
Sex
All
Sponsor
Albert Einstein College of Medicine
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Walking Speed During Single and Dual-task Walking Conditions
-3.33; -0.53; 5.89; -10.55
SECONDARY
Change in Cognitive Performance During Walking While Talking
0.19; -1.54
SECONDARY
Change in Blood-oxygen-level-dependent (BOLD) Signal During Dual-task Imagined Walking While Talking (iWWT) Conditions
-2.98; -3.07
SECONDARY
Change in Trail Making Test Form A
-0.72; -1.45
SECONDARY
Change in Trail Making Test Form B
4.49; -9.54
SECONDARY
Change in Trail Making Test Form B Minus Form A
5.22; -8.09
SECONDARY
Change in Letter Number Sequencing Task Score
-0.55; 0.61
SECONDARY
Change in Stroop Interference Test: Color-Word Minus Color Score
-8.38; -14.47
SECONDARY
Change in Flanker Interference Task
-49.55; -94.69
SECONDARY
Change in Stride Length
3.08; -11.49
SECONDARY
Change in Gait Variability
-0.17; 1.81
SECONDARY
Change in Gait Domains

Summary

The investigators propose a single-blind randomized clinical trial to determine if seniors show improved mobility (walking speed) and cognition following motor imagery (imagined walking) training. They hypothesize that imagined walking can be used as a rehabilitative tool for improving walking speed and cognition in the elderly, because it engages and strengthens similar neural systems as actual walking and cognition.

Eligibility Criteria

Inclusion Criteria

  • Adults between 65 and 85 years and older, residing in the community.
  • Able to speak English at a level sufficient to undergo study procedures.
  • Plan to be in the area for the next 3 months.

Exclusion Criteria

  • Presence of dementia (telephone-based memory impairment screen 1)
  • Presence of gait disorder diagnosed by clinician (e.g. neuropathy).
  • Any medical condition or chronic medication use (e.g. neuroleptics) that will compromise safety or affect cognitive functioning.
  • Terminal illness with life expectancy <12 months.
  • Progressive, degenerative neurologic disease (e.g. Parkinson's disease, ALS).
  • Major psychiatric disorders such as Schizophrenia.
  • Pacemaker or any permanent metal implants like hip prosthesis (other than tooth fillings) and claustrophobia.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02762604). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search